Ibrahim El Houssieny joins us at the EHA annual meeting in Amsterdam to discuss the most important recent therapeutic advances and manufacturing of CAR-T cells. This is part 1 of his interview, part two can be viewed here.
1. What have been the most exciting recent developments in CAR-T cell therapy? (0:05)
2. Which patient subgroups are most likely to respond to this therapeutic approach? (1:40)
3. What are the major challenges in the manufacturing of CAR-T cells? (3:28)
Ibrahim El Houssieny has no conflicts of interest to declare in relation to this video.
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Immunotherapy
Omid Hamid, ASCO 2021: Nemvaleukin Alfa and the ARTISTRY-2 Trial
touchONCOLOGY joins Dr Omid Hamid (Chief, Translational Research and Immunotherapy, Director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, Los Angeles, CA, USA) at ASCO 2021 to discuss nemvaleukin alfa and the ARTISTRY-2 trial. The abstract ‘Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2’ (NCT03861793) (abstract number 2552) was presented […]
Leisha A Emens, ESMO 2020 – Overall Survival Analysis from IMpassion 130 in Triple-negative Breast Cancer
Prof. Leisha A Emens joins touchONCOLOGY to discuss the final overall survival analysis of the phase III IMpassion 130 study investigating atezolizumab plus nab-paclitaxel versus placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Prof. Emens explores what we can learn from these findings, as well as the failure of IMpassion […]
IBRAHIM EL HOUSSIENY, EHA 2019 – CAR-T cells and manufacturing (Part 2)
Ibrahim El Houssieny joins us at the EHA annual meeting in Amsterdam to discuss the most important recent therapeutic advances and manufacturing of CAR-T cells. This is part 2 of his interview, part one can be viewed here. Questions 1. How can we mitigate the toxicities associated with CAR-T cell therapy? (0:05) 2. What is […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!